We investigate the personalisation and prediction accuracy of mathematical models for white blood cell (WBC) count dynamics during consolidation treatment using intermediate or high-dose cytarabine (Ara-C) in acute myeloid leukaemia (AML). Ara-C is the clinically most relevant cytotoxic agent for AML treatment. We extend a mathematical model of myelosuppression and a pharmacokinetic model of Ara-C with different hypotheses of Ara-C’s pharmacodynamic effects. We cross-validate the 12 model variations using dense WBC count measurements from 23 AML patients. Surprisingly, the prediction accuracy remains satisfactory in each of the models despite different modelling hypotheses. Therefore, we compare average clinical and calculated WBC recovery times for different Ara-C schedules as a successful methodology for model discrimination. As a result, a new hypothesis of a secondary pharmacodynamic effect on the proliferation rate seems plausible. Furthermore, we demonstrate the impact of treatment timing on subsequent nadir values based on personalised predictions as a possibility for influencing/controlling myelosuppression.
1 November 2021 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation. NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.
1 December 2020 in IEEE Transactions on Biomedical Engineering
Objective: Neutropenia is an adverse event commonly arising during intensive chemotherapy of acute myeloid leukemia (AML). It is often associated with infectious complications. Mathematical modeling, simulation, and optimization of the treatment process would be a valuable tool to support clinical decision making, potentially resulting in less severe side effects and deeper remissions. However, until now, there has been no validated mathematical model available to simulate the effect of chemotherapy treatment on white blood cell (WBC) counts and leukemic cells simultaneously. Methods: We developed a population pharmacokinetic/pharmacodynamic (PK/PD) model combining a myelosuppression model considering endogenous granulocyte-colony stimulating factor (G-CSF), a PK model for cytarabine (Ara-C), a subcutaneous absorption model for exogenous G-CSF, and a two-compartment model for leukemic blasts. This model was fitted to data of 44 AML patients during consolidation therapy with a novel Ara-C plus G-CSF schedule from a phase II controlled clinical trial. Additionally, we were able to optimize treatment schedules with respect to disease progression, WBC nadirs, and the amount of Ara-C and G-CSF. Results: The developed PK/PD model provided good prediction accuracies and an interpretation of the interaction between WBCs, G-CSF, and blasts. For 14 patients (those with available bone marrow blast counts), we achieved a median 4.2-fold higher WBC count at nadir, which is the most critical time during consolidation therapy. The simulation results showed that relative bone marrow blast counts remained below the clinically important threshold of 5%, with a median of 60% reducion in Ara-C. Conclusion: These in silico findings demonstrate the benefits of optimized treatment schedules for AML patients. Significance: Until 2017, no new drug had been approved for the treatment of AML, fostering the optimal use of currently available drugs.
Nonlinear model predictive control has been established as a powerful methodology to provide feedback for dynamic processes over the last decades. In practice it is usually combined with parameter and state estimation techniques, which allows to cope with uncertainty on many levels. To reduce the uncertainty it has also been suggested to include optimal experimental design into the sequential process of estimation and control calculation. Most of the focus so far was on dual control approaches, i.e., on using the controls to simultaneously excite the system dynamics (learning) as well as minimizing a given objective (performing). We propose a new algorithm, which sequentially solves robust optimal control, optimal experimental design, state and parameter estimation problems. Thus, we decouple the control and the experimental design problems. This has the advantages that we can analyze the impact of measurement timing (sampling) independently, and is practically relevant for applications with either an ethical limitation on system excitation (e.g., chemotherapy treatment) or the need for fast feedback. The algorithm shows promising results with a reduction of parameter uncertainties for the Lotka-Volterra fishing benchmark example.
12 March 2018 in Journal of Optimization Theory and Applications
Predicting pharmacokinetic (PK) profiles from molecular structures constitutes a significant advancement in pharmaceutical research with substantial implications for expediting the entire drug discovery process. Our investigation presents a comprehensive comparative analysis of five distinct methodological frameworks for predicting rat plasma concentration-time profiles: four approaches that integrate mechanistic modeling with computational techniques, and one approach employing pure machine learning (ML) architecture without physiological constraints. As reference (1), we used a method that predicts non-compartmental analysis (NCA) parameters to predict plasma PK profiles with a one-compartmental PK model (NCA-ML). Alternative approaches include: (2) a physiologically based PK (PBPK) model utilizing ML-predicted in vitro characteristics; (3) CMT-ML, where neural networks predict compartmental PK model parameters; (4) CMT-PINN, employing physics-informed neural networks; and (5) PURE-ML, using decision trees to predict concentration values at specific timepoints based on predicted volume of distribution and clearance. Assessment using multiple performance metrics demonstrated that the CMT-PINN approach achieved superior predictivity for PK profiles. Models trained directly on concentration-time, rather than derived PK parameters, delivered markedly improved predictive performance, particularly when working with limited training datasets. Our findings confirm the viability of predicting PK behavior from molecular structures before synthesis, representing a significant advancement for subsequent design. Implementation of these computational approaches enables informed compound selection early in the discovery pipeline, concentrating valuable resources for advanced preclinical investigations on only the most promising candidates, with anticipated beneficial effects on overall development timelines.